VANCOUVER, BC, June 29, 2021 /CNW/ - Rakovina Therapeutics Inc.
(TSXV: RKV) ("the Company"), a biopharmaceutical company
committed to advancing new cancer therapies based on novel
DNA-damage response technologies, is pleased to announce the
results of voting at its 2021 Annual General Meeting of
Shareholders held on June 29, 2021
(the "Meeting").
All five members of the Company's Board of Directors named as
nominees in its management information circular (the "Circular")
were elected as Directors: Jeffrey
Bacha, Dr. Dennis Brown, Dr.
Julie Cherrington, Alfredo De Lucrezia and Michael Liggett.
Additional voting results from the Meeting include: (i)
shareholders approved the appointment of Davidson & Company LLP
as the Company's auditor and (ii) disinterested shareholders
approved the Company's long-term incentive plan as set out in the
Circular. All other resolutions set out in the Circular were also
approved by shareholders.
About Rakovina Therapeutics Inc.
Rakovina Therapeutics Inc. is focused on the development
of new cancer treatments based on novel DNA-damage response
technologies. The Company has established a pipeline of
DNA-damage response inhibitors with the goal of advancing one or
more drug candidates into human clinical trials and obtaining
marketing approval for new cancer therapeutics from Health Canada,
the United States Food and Drug Administration and similar
international regulatory agencies. Further information may be
found at www.rakovinatherapeutics.com.
SOURCE Rakovina Therapeutics Inc.